How should colchicine be dosed and monitored for acute pericarditis and post‑myocardial infarction anti‑inflammatory therapy?

Colchicine for Cardiovascular Indications: Dosing and Monitoring

For acute pericarditis, colchicine 0.5 mg twice daily (≥70 kg) or 0.5 mg once daily (<70 kg) for 3 months is recommended as first-line adjunctive therapy with NSAIDs, while for post-MI patients, low-dose colchicine 0.5 mg daily may be reasonable to reduce major adverse cardiovascular events, though the evidence is less robust and mortality benefit remains unproven.

Acute Pericarditis

Dosing Protocol

Colchicine is Class I, Level A recommendation as first-line adjunctive therapy for acute pericarditis 1. The dosing is weight-based:

• ≥70 kg: 0.5 mg twice daily for 3 months
• <70 kg: 0.5 mg once daily for 3 months
• No loading dose required
• Tapering is not mandatory, though can consider 0.5 mg every other day (<70 kg) or 0.5 mg once daily (≥70 kg) in final weeks 1

This regimen reduces recurrence risk by approximately 50%, with number needed to treat of 4 2. The 3-month duration is critical—shorter courses increase recurrence rates from 15-30% to potentially 50% 1.

Monitoring Strategy

• C-reactive protein (CRP) should guide treatment duration and assess therapeutic response 1
• Continue therapy until symptom resolution AND CRP normalization
• Monitor for gastrointestinal intolerance (occurs in ~10% but rarely requires discontinuation) 3
• Exercise restriction until symptoms resolve, CRP normalizes, and ECG/echocardiogram normalize (minimum 3 months for athletes) 1

Recurrent Pericarditis

For recurrences, extend colchicine to ≥6 months at the same weight-based doses, without loading dose 1. This longer duration improves remission rates and prevents subsequent recurrences.

Post-Myocardial Infarction

Evidence Quality and Recommendation Strength

The 2025 ACC/AHA guideline assigns colchicine a Class 2b (may be reasonable), Level B-R recommendation for post-ACS patients 4. This weaker recommendation reflects mixed trial results and concerning safety signals.

Dosing Protocol

• 0.5 mg once daily (or 0.6 mg once daily per FDA labeling) 4, 5
• Initiate within 30 days post-MI (median 14 days in COLCOT) 4, 6
• Duration: minimum 1 year, with benefit appearing to increase with longer follow-up 7

Critical Safety Considerations

Important caveat: The COPS trial showed numerically more deaths with colchicine (8 vs 1, P=0.017), driven by non-cardiovascular deaths, when initiated during index hospitalization 4. This raises concern about very early initiation in acute settings.

The COLCOT trial demonstrated 32% reduction in composite cardiovascular outcomes, but this was driven primarily by:

• Reduced urgent revascularization for angina
• Reduced stroke (HR 0.26)
• NOT by mortality reduction (HR 0.84, not significant) 4, 6

Monitoring Requirements

• Gastrointestinal symptoms: Most common adverse effect (9.7% vs 8.9% placebo) 6
• Pneumonia risk: Increased serious adverse events (0.9% vs 0.4%, P=0.03) 6
• Drug interactions: Critical to screen for CYP3A4 and P-glycoprotein inhibitors 5

Dose Adjustments for Renal/Hepatic Impairment

Renal Impairment (applies to both indications)

• Mild-moderate (CrCl 30-80 mL/min): No dose adjustment needed, but monitor closely 5
• Severe (CrCl <30 mL/min): Start 0.3 mg daily, increase cautiously with monitoring 5
• Dialysis: 0.3 mg twice weekly for prophylaxis; single 0.6 mg dose for acute treatment (no more than once every 2 weeks) 5

Hepatic Impairment

• Mild-moderate: No adjustment, monitor closely 5
• Severe: Consider dose reduction 5

Absolute Contraindications

Do not use colchicine with 5:

• Strong CYP3A4 inhibitors (clarithromycin, ketoconazole, ritonavir, atazanavir) in patients with renal or hepatic impairment
• Severe renal failure (CrCl <15 mL/min) with P-glycoprotein inhibitors
• Blood dyscrasias

Drug Interaction Management

When moderate CYP3A4 inhibitors (diltiazem, verapamil, erythromycin) are unavoidable 5:

• Pericarditis: Reduce to 0.3 mg twice daily or 0.6 mg once daily
• Post-MI: Reduce to 0.3 mg once daily or 0.3 mg every other day

Clinical Decision Algorithm

For Acute Pericarditis:

1. Confirm diagnosis (chest pain, friction rub, ECG changes, effusion)
2. Check renal function, hepatic function, medication list
3. Start colchicine 0.5 mg once or twice daily (weight-based) + NSAID
4. Monitor CRP weekly initially
5. Continue 3 months minimum, until symptom resolution + CRP normalization
6. Restrict exercise until complete resolution

For Post-MI:

1. Consider only if >3 days post-MI (avoid during acute hospitalization given COPS mortality signal)
2. Screen for drug interactions, renal/hepatic impairment
3. Assess gastrointestinal tolerance and pneumonia risk factors
4. If proceeding: 0.5 mg daily for ≥1 year
5. Recognize this reduces urgent revascularization and stroke, NOT mortality
6. Monitor for GI intolerance and infection

The key distinction: Colchicine has strong, consistent evidence in pericarditis (Class I) but weaker, mixed evidence post-MI (Class 2b), with no mortality benefit and potential early harm if initiated too acutely.